Heron Therapeutics (HRTX) Scheduled to Post Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX) will be issuing its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Heron Therapeutics has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.08. The company had revenue of $34.23 million for the quarter, compared to the consensus estimate of $30.98 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Heron Therapeutics Stock Performance

HRTX opened at $2.61 on Friday. The company has a market cap of $393.17 million, a PE ratio of -3.03 and a beta of 1.73. The stock has a 50-day moving average of $2.71 and a 200-day moving average of $2.03. Heron Therapeutics has a 52-week low of $0.50 and a 52-week high of $3.22.

Analyst Upgrades and Downgrades

HRTX has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price target on shares of Heron Therapeutics in a research note on Thursday, April 11th. StockNews.com upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Finally, Capital One Financial began coverage on Heron Therapeutics in a research note on Tuesday, April 23rd. They set an “overweight” rating and a $6.00 target price for the company.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.